Patent
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
Thomas W. Dubensky,David B. Kanne,Leong Meredith Lai Ling,Edward E. Lemmens,Glickman Laura Hix +4 more
Reads0
Chats0
TLDR
In this paper, a cyclic-di-nucleotide (CDN) immune stimulator that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes).Abstract:
It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.read more
Citations
More filters
Patent
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
Thomas W. Dubensky,David B. Kanne,Meredith Lai Ling Leong,Laura Hix Glickman,Russell E. Vance,Edward Emile Lemmens +5 more
TL;DR: In this article, a cyclic-di-nucleotide (CDN) immune stimulator that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes).
Patent
Cyclic di-nucleotide compounds as sting agonists
Michael D. Altman,Brian M. Andresen,Wonsuk Chang,Matthew Lloyd Childers,Jared N. Cumming,Andrew M. Haidle,Timothy J. Henderson,James P. Jewell,Rui Liang,Jongwon Lim,Hong Liu,Min Lu,Alan B. Northrup,Ryan D. Otte,Tony Siu,Benjamin Wesley Trotter,Quang T. Truong,Shawn P. Walsh,Kake Zhao +18 more
TL;DR: In this article, a class of polycyclic compounds of general formula (II), of general form (II'), or of general condition (II) was defined, which may be useful as inductors of type I interferon production, specifically as STING active agents.
Patent
Compositions and methods for inhibiting "stimulator of interferon gene" -dependent signalling
TL;DR: In this paper, cyclic-di-nucleotide (CDN) compounds are provided in the form of a composition comprising one or more cyclic purine dinucleotides which inhibit STING-dependent TBK1 activation and the resulting production of type I interferon.
Patent
Compostions and methods for cancer immunotherapy
TL;DR: In this article, a combination therapy which relies on a small molecule immune stimulator - cyclic-di-nucleotide (CDN) - that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of GM-CSF.
Patent
Cyclic di-nucleotides as modulators of STING
TL;DR: A compound of formula (I) or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation is defined in this article.
References
More filters
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Book
Remington : The Science and Practice of Pharmacy
TL;DR: Remington: The Science and Practice of Pharmacy now includes six months free online access to Facts and Comparisons's DrugfactsPlus, the leading source of drug information and pharmacist tools on the Internet.
Journal ArticleDOI
The blockade of immune checkpoints in cancer immunotherapy
TL;DR: Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Journal ArticleDOI
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Taro Kawai,Shizuo Akira +1 more
TL;DR: Recent advances that have been made by research into the role of TLR biology in host defense and disease are described.
Journal ArticleDOI
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Ian F. Tannock,Ronald de Wit,William R. Berry,Jozsef Horti,Anna Pluzanska,Kim N. Chi,Stéphane Oudard,Christine Theodore,Nicholas D. James,Ingela Turesson,Mark Rosenthal,Mario A. Eisenberger +11 more
TL;DR: When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.